Scientific articleObjective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either buserelin or orchiectomy Disease aggressivity and its association with response and outcome
References (26)
Suppression of testicular steroidogenesis by the GnRH agonistic analogue, Buserelin (HOE 766), in patients with prostatic cancer: studies in relation to dose and route of administration
J Steroid Biochem
(1983)- et al.
Yttrium hypophysectomy in the management of metastatic carcinoma of the prostate gland in 13 patients
J Urol
(1968) - et al.
Studies on prostate cancer: the effects of castration, of estrogens, and of androgen injection of serum phosphatase in metastatic carcinoma of the prostate
Cancer Res
(1941) Treatment and survival of patients with cancer of the prostate
Surg Gynecol Obstet
(1967)- et al.
Endocrine control of prostatic carcinoma
JAMA
(1950) Doxorubicin, Mitomycin and 5-FU (DMF) in the treatment of hormone-resistant Stage D prostate cancer: a preliminary report
Cancer Treat Rep
(1982)Radiation therapy for cancer of the prostate
Tumour growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists
- et al.
Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic cancer
The Prostate
(1983) Preliminary results on the clinical efficiency and safety of androgen inhibition by an LHRH agonistic alone or combined with an anti-androgen in the treatment of prostatic carcinoma
The Prostate
(1983)
Sustained suppression of testosterone production by the luteinizing-hormone, releasing hormone agonist Buserelin in patients with advanced prostate carcinoma: a new therapeutic approach
Lancet
(1982)
Long-term effects of administration of a gonadotropin-releasing hormone superagonistic analog in men with prostatic cancer
J Clin Endocrinol Metab
(1984)
Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH
Med Onc Tumour Pharmacother
(1984)
Cited by (45)
Mechanisms of bone metastasis in prostate cancer: clinical implications
2008, Best Practice and Research: Clinical Endocrinology and MetabolismCitation Excerpt :Patients that initially present with localized cancer (confined to the prostate gland) can be treated by potentially curative therapies such as radical prostatectomy or radiation therapy (either external-beam radiotherapy or sealed-source radiotherapy, also known as brachytherapy). Although the majority of patients present with clinically localized disease, a sizeable proportion of these patients will ultimately relapse, with the reported 5-year failure rate ranging from 17% to 34%.11,54–57 This indicates the residual postoperative presence of locally invasive, circulating and/or distant micrometastatic cancer cells.58
Skeletal metastases in advanced prostate cancer: cell biology and therapy
1995, Critical Reviews in Oncology and HematologyLuteinising Hormone Releasing Hormone
1993, Pharmacochemistry Library
Copyright © 1986 Published by Elsevier Inc.